Drugs / Empagliflozine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02918591 | Nov 2017 → Mar 2018 | type 2 diabetes mellitus | Tel Aviv University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Empagliflozine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02918591 ↗ |
| Action | Inhibit | “Empagliflozine is a selective inhibitor of renal sodium-glucose co-transporters (SGLTs)” NCT02918591 ↗ |